Breathe Well Live Well
FiercePharma |
PhIII data puts AZ one step closer to severe-asthma showdown with GSK
FiercePharma Last week, the British drugmaker announced that its candidate for severe asthma with eosinophilic inflammation–benralizumab–had nailed its primary endpoint in two Phase III studies, beating out placebo at paring down the annual asthma exacerbation … |
View full post on asthma – Google News
Reuters UK |
AstraZeneca squares off against Roche in blockbuster PhIII asthma showdown
FierceBiotech Receptos, meanwhile, in-licensed an IL-13 drug from AbbVie after the pharma company decided to de-prioritize its respiratory efforts, including a program for asthma. Receptos is testing RPC4046 for Eosinophilic esophagitis, an orphan disease, and … AstraZeneca starts final-stage tests on severe asthma drug AstraZeneca share price: Drugmaker starts late-stage asthma drug trial AZ severe asthma drug tralokinumab goes into Phase III |
View full post on asthma – Google News